Enliven Therapeutics Announces Executive and Board Changes
Ticker: ELVN · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1672619
| Field | Detail |
|---|---|
| Company | Enliven Therapeutics, Inc. (ELVN) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2025 |
| Risk Level | medium |
| Pages | 9 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.001, $23 billion, $660,000, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-composition
TL;DR
Enliven Therapeutics shakes up leadership and exec pay; board changes announced.
AI Summary
Enliven Therapeutics, Inc. announced on December 9, 2025, changes in its board and executive team, including the departure of a director and the appointment of new officers. The company also disclosed compensatory arrangements for certain officers and provided a Regulation FD disclosure. This filing also includes financial statements and exhibits.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially when coupled with compensatory arrangements, can indicate internal shifts that may carry strategic or financial implications.
Key Players & Entities
- Enliven Therapeutics, Inc. (company) — Registrant
- December 9, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39247 (identifier) — Commission File Number
- 81-1523849 (identifier) — IRS Employer Identification No.
- 6200 Lookout Road, Boulder, Colorado 80301 (address) — Principal executive offices
- 720 647-8519 (phone_number) — Registrant's telephone number
FAQ
What specific roles have been affected by the changes in directors or officers?
The filing indicates a departure of a director and the appointment of certain officers, along with compensatory arrangements for these officers, but does not specify the exact roles affected in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 9, 2025.
What is the primary business of Enliven Therapeutics, Inc. according to the filing?
Enliven Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the state of incorporation for Enliven Therapeutics, Inc.?
The company is incorporated in Delaware.
What is the Commission File Number for Enliven Therapeutics, Inc.?
The Commission File Number is 001-39247.
Filing Stats: 2,594 words · 10 min read · ~9 pages · Grade level 11.1 · Accepted 2025-12-11 09:11:03
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ELVN The Nasdaq Global Se
- $23 billion — , and the commercialization plans for a $23 billion business. Prior to Roche/Genentech, Mr.
- $660,000 — Fair will have an annual base salary of $660,000. Annual Bonus – Mr. Fair is eligible
- $500,000 — z will have annual base compensation of $500,000. Annual Bonus – Mr. Kintz will remain
Filing Documents
- d937094d8k.htm (8-K) — 50KB
- d937094dex101.htm (EX-10.1) — 22KB
- d937094dex102.htm (EX-10.2) — 52KB
- d937094dex103.htm (EX-10.3) — 83KB
- d937094dex991.htm (EX-99.1) — 15KB
- g937094g1211025922373.jpg (GRAPHIC) — 3KB
- 0001193125-25-315196.txt ( ) — 396KB
- elvn-20251209.xsd (EX-101.SCH) — 3KB
- elvn-20251209_lab.xml (EX-101.LAB) — 18KB
- elvn-20251209_pre.xml (EX-101.PRE) — 11KB
- d937094d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits See the Exhibit Index below, which is incorporated by reference herein. EXHIBIT INDEX Exhibit No. Description 10.1+#* Richard Fair Offer Letter, effective December 11, 2025. 10.2+ Richard Fair Change in Control and Severance Agreement, effective December 11, 2025. 10.3+ Enliven Therapeutics, Inc. 2025 Inducement Equity Incentive Plan and related form of stock option agreement. 99.1 Press Release, dated December 11, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). + Management contract or compensatory plan. # Certain exhibits or schedules to this exhibit have been omitted in compliance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. * Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Enliven Therapeutics, Inc. Date: December 11, 2025 By: /s/ Benjamin Hohl Name: Benjamin Hohl Title: Chief Financial Officer and Head of Corporate Development